Assessment of the risk of antiangiogenic agents before and after surgery

Bailey, Christina E.; Parikh, Alexander A.

doi:10.1016/j.ctrv.2018.05.002

Cited by 13 publications

(8 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peri-surgical antiangiogenesis may be associated with safety concerns because it is an essential step in wound healing 37 . In former trials, neoadjuvant bevacizumab increased incidences of postoperative anastomotic leak and wound healing complications after oesophagogastrectomy 38 .…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer

Xie

et al. 2023

Nat Commun

View full text Add to dashboard Cite

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in late-stage gastric cancer, but their efficacy in the neoadjuvant/conversion setting is unclear. In this single-armed, phase II, exploratory trial (NCT03878472), we evaluate the efficacy of a combination of ICI (camrelizumab), antiangiogenesis (apatinib), and chemotherapy (S-1 ± oxaliplatin) for neoadjuvant/conversion treatment of cT4a/bN+ gastric cancer. The primary endpoints are pathological responses and their potential biomarkers. Secondary endpoints include safety, objective response, progression-free survival, and overall survival. Complete and major pathological response rates are 15.8% and 26.3%. Pathological responses correlate significantly with microsatellite instability status, PD-L1 expression, and tumor mutational burden. In addition, multi-omics examination reveals several putative biomarkers for pathological responses, including RREB1 and SSPO mutation, immune-related signatures, and a peripheral T cell expansion score. Multi-omics also demonstrates dynamic changes in dominant tumor subclones, immune microenvironments, and T cell receptor repertoires during neoadjuvant immunotherapy. The toxicity and post-surgery complications are limited. These data support further validation of ICI- and antiangiogenesis-based neoadjuvant/conversion therapy in large randomized trials and provide candidate biomarkers.

show abstract

Section: Discussionmentioning

confidence: 99%

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer

Xie

et al. 2023

Nat Commun

View full text Add to dashboard Cite

show abstract

“…217,218 Some antiangiogenic agents, particularly bevacizumab, have been associated with bleeding, thrombosis, gastrointestinal perforation, and impaired wound healing. 219 It is believed that the perioperative use of these agents would increase the risk of surgical wound complications, including dehiscence, surgical site bleeding, and/or wound infection. The long half-life of bevacizumab (about 20 days) may lead to a greater risk of wound-healing complications with this agent.…”

Section: Perioperative Management Of Systemic Agents For Bmmentioning

confidence: 99%

An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma

Hasanov

Yeboa

Tucker

et al. 2022

CA A Cancer J Clinicians

View full text Add to dashboard Cite

Brain metastases are a challenging manifestation of renal cell carcinoma. We have a limited understanding of brain metastasis tumor and immune biology, drivers of resistance to systemic treatment, and their overall poor prognosis. Current data support a multimodal treatment strategy with radiation treatment and/or surgery. Nonetheless, the optimal approach for the management of brain metastases from renal cell carcinoma remains unclear. To improve patient care, the authors sought to standardize practical management strategies. They performed an unstructured literature review and elaborated on the current management strategies through an international group of experts from different disciplines assembled via the network of the International Kidney Cancer Coalition. Experts from different disciplines were administered a survey to answer questions related to current challenges and unmet patient needs. On the basis of the integrated approach of literature review and survey study results, the authors built algorithms for the management of single and multiple brain metastases in patients with renal cell carcinoma. The literature review, consensus statements, and algorithms presented in this report can serve as a framework guiding treatment decisions for patients. CA Cancer J Clin. 2022;72:454‐489.

show abstract

“…Two well-known side effects of anti-angiogenic therapy that go hand in hand are the increased rate of hemorrhage and the inhibited wound healing process, both of which are determining factors for the timing of surgical procedures ( 65 ). Pulmonary hemorrhage with fatal outcome has been reported for non-small cell lung cancer patients with different anti-angiogenesis inhibitors, such as bevacizumab, ramucirumab, sunitinib, axitinib, and motesanib.…”

Section: Limitations and Side Effects Of Anti-angiogenic Therapiesmentioning

confidence: 99%

“…Pulmonary hemorrhage with fatal outcome has been reported for non-small cell lung cancer patients with different anti-angiogenesis inhibitors, such as bevacizumab, ramucirumab, sunitinib, axitinib, and motesanib. A small percentage of gastrointestinal tumor patients developed bleeding at the tumor sites, while central nervous bleeding has also been reported ( 61 , 65 ). Impaired wound healing is a common issue.…”

Section: Limitations and Side Effects Of Anti-angiogenic Therapiesmentioning

confidence: 99%

“…Angiogenesis is a pivotal part of the wound healing process, mediated by VEGF and other growth factors, thus is expected that VEGF inhibition hampers the inflammatory and granulation wound healing phases, pivotal for the wound healing process. As an alternative, milder anti-angiogenic treatments have been proposed to overcome this issue ( 66 ).To avoid wound healing deficiency of the surgical area anti-angiogenic treatment has to be terminated for at least four weeks before the surgical procedure so that the body will “wash out” the drug’s effects ( 61 , 65 ).…”

Section: Limitations and Side Effects Of Anti-angiogenic Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential

Lahooti¹,

Poudel

Mikelis³

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Angiogenesis is a key mechanism for tumor growth and metastasis and has been a therapeutic target for anti-cancer treatments. Intensive vascular growth is concomitant with the rapidly proliferating tumor cell population and tumor outgrowth. Current angiogenesis inhibitors targeting either one or a few pro-angiogenic factors or a range of downstream signaling molecules provide clinical benefit, but not without significant side effects. miRNAs are important post-transcriptional regulators of gene expression, and their dysregulation has been associated with tumor progression, metastasis, resistance, and the promotion of tumor-induced angiogenesis. In this mini-review, we provide a brief overview of the current anti-angiogenic approaches, their molecular targets, and side effects, as well as discuss existing literature on the role of miRNAs in angiogenesis. As we highlight specific miRNAs, based on their activity on endothelial or cancer cells, we discuss their potential for anti-angiogenic targeting in cancer as adjuvant therapy and the importance of angiogenesis being evaluated in such combinatorial approaches.

show abstract

Assessment of the risk of antiangiogenic agents before and after surgery

Cited by 13 publications

References 76 publications

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer

Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer

An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma

MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential

Contact Info

Product

Resources

About